Correlation Between Unicycive Therapeutics and SAB Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Unicycive Therapeutics and SAB Biotherapeutics, you can compare the effects of market volatilities on Unicycive Therapeutics and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and SAB Biotherapeutics.
Diversification Opportunities for Unicycive Therapeutics and SAB Biotherapeutics
0.54 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Unicycive and SAB is 0.54. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and SAB Biotherapeutics go up and down completely randomly.
Pair Corralation between Unicycive Therapeutics and SAB Biotherapeutics
Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 1.29 times more return on investment than SAB Biotherapeutics. However, Unicycive Therapeutics is 1.29 times more volatile than SAB Biotherapeutics. It trades about 0.05 of its potential returns per unit of risk. SAB Biotherapeutics is currently generating about 0.01 per unit of risk. If you would invest 45.00 in Unicycive Therapeutics on August 31, 2024 and sell it today you would earn a total of 24.00 from holding Unicycive Therapeutics or generate 53.33% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 99.79% |
| Values | Daily Returns |
Unicycive Therapeutics vs. SAB Biotherapeutics
Performance |
| Timeline |
| Unicycive Therapeutics |
| SAB Biotherapeutics |
Unicycive Therapeutics and SAB Biotherapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Unicycive Therapeutics and SAB Biotherapeutics
The main advantage of trading using opposite Unicycive Therapeutics and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.| Unicycive Therapeutics vs. Cue Biopharma | Unicycive Therapeutics vs. Eliem Therapeutics | Unicycive Therapeutics vs. Inhibrx | Unicycive Therapeutics vs. Molecular Partners AG |
| SAB Biotherapeutics vs. Processa Pharmaceuticals | SAB Biotherapeutics vs. Third Harmonic Bio | SAB Biotherapeutics vs. Cingulate Warrants | SAB Biotherapeutics vs. Anebulo Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Complementary Tools
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |